Advertisement
Screener

HALOZYME THERAPEUTICS, INC. (HALO) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

HALOZYME THERAPEUTICS, INC. Operating Cash Flow

HALOZYME THERAPEUTICS, INC. (HALO) reported Operating Cash Flow of $420.97 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06

  • HALOZYME THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $240.89M, a 141.59% increase year-over-year.
  • HALOZYME THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $180.08M, a 16.77% increase year-over-year.
  • HALOZYME THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $219.03M, a 22.73% increase year-over-year.
  • HALOZYME THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $178.60M, a 54.80% increase year-over-year.
  • HALOZYME THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was $651.56M, a 36.01% increase from fiscal 2024.
  • HALOZYME THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was $479.06M, a 23.29% increase from fiscal 2023.
  • HALOZYME THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was $388.57M, a 61.83% increase from fiscal 2022.
  • HALOZYME THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was $240.11M, a 19.81% decline from fiscal 2021.
Period endNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2026-06-30$240.89M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$420.97M
10-Q · filed 2026-08-06
$640.00M
derived: sum of 3 quarters · filed 2026-08-06
$818.60M
derived: sum of 4 quarters · filed 2026-08-06
2026-03-31$180.08M
10-Q · filed 2026-05-11
$399.11M
derived: sum of 2 quarters · filed 2026-05-11
$577.70M
derived: sum of 3 quarters · filed 2026-05-11
$677.41M
derived: sum of 4 quarters · filed 2026-08-06
2025-12-31$219.03M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
$397.63M
derived: sum of 2 quarters · filed 2026-02-17
$497.34M
derived: sum of 3 quarters · filed 2026-08-06
$651.56M
10-K · filed 2026-02-17
2025-09-30$178.60M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03
$278.31M
derived: sum of 2 quarters · filed 2026-08-06
$432.53M
10-Q · filed 2025-11-03
$611.00M
derived: sum of 4 quarters · filed 2026-08-06
2025-06-30$99.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06
$253.93M
10-Q · filed 2026-08-06
$432.40M
derived: sum of 3 quarters · filed 2026-08-06
$547.77M
derived: sum of 4 quarters · filed 2026-08-06
2025-03-31$154.22M
10-Q · filed 2026-05-11
$332.69M
derived: sum of 2 quarters · filed 2026-05-11
$448.06M
derived: sum of 3 quarters · filed 2026-05-11
$503.86M
derived: sum of 4 quarters · filed 2026-05-11
2024-12-31$178.47M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
$293.84M
derived: sum of 2 quarters · filed 2026-02-17
$349.64M
derived: sum of 3 quarters · filed 2026-02-17
$479.06M
10-K · filed 2026-02-17
2024-09-30$115.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03
$171.17M
derived: sum of 2 quarters · filed 2025-11-03
$300.60M
10-Q · filed 2025-11-03
$402.95M
derived: sum of 4 quarters · filed 2026-02-17
2024-06-30$55.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
$185.22M
10-Q · filed 2025-08-05
$287.57M
derived: sum of 3 quarters · filed 2026-02-17
$419.99M
derived: sum of 4 quarters · filed 2026-02-17
2024-03-31$129.43M
10-Q · filed 2025-05-06
$231.78M
derived: sum of 2 quarters · filed 2026-02-17
$364.19M
derived: sum of 3 quarters · filed 2026-02-17
$431.03M
derived: sum of 4 quarters · filed 2026-02-17
2023-12-31$102.35M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17
$234.76M
derived: sum of 2 quarters · filed 2026-02-17
$301.61M
derived: sum of 3 quarters · filed 2026-02-17
$388.57M
10-K · filed 2026-02-17
2023-09-30$132.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31
$199.25M
derived: sum of 2 quarters · filed 2024-10-31
$286.22M
10-Q · filed 2024-10-31
$368.67M
derived: sum of 4 quarters · filed 2025-02-18
2023-06-30$66.84M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06
$153.81M
10-Q · filed 2024-08-06
$236.26M
derived: sum of 3 quarters · filed 2025-02-18
$305.89M
derived: sum of 4 quarters · filed 2025-02-18
2023-03-31$86.96M
10-Q · filed 2024-05-07
$169.42M
derived: sum of 2 quarters · filed 2025-02-18
$239.05M
derived: sum of 3 quarters · filed 2025-02-18
$279.28M
derived: sum of 4 quarters · filed 2025-02-18
2022-12-31$82.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18
$152.09M
derived: sum of 2 quarters · filed 2025-02-18
$192.31M
derived: sum of 3 quarters · filed 2025-02-18
$240.11M
10-K · filed 2025-02-18
2022-09-30$69.64M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06
$109.86M
derived: sum of 2 quarters · filed 2023-11-06
$157.66M
10-Q · filed 2023-11-06
$240.17M
derived: sum of 4 quarters · filed 2024-02-20
2022-06-30$40.23M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08
$88.02M
10-Q · filed 2023-08-08
$170.54M
derived: sum of 3 quarters · filed 2024-02-20
$292.28M
derived: sum of 4 quarters · filed 2024-02-20
2022-03-31$47.80M
10-Q · filed 2023-05-09
$130.31M
derived: sum of 2 quarters · filed 2024-02-20
$252.05M
derived: sum of 3 quarters · filed 2024-02-20
$288.94M
derived: sum of 4 quarters · filed 2024-02-20
2021-12-31$82.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20
$204.25M
derived: sum of 2 quarters · filed 2024-02-20
$241.14M
derived: sum of 3 quarters · filed 2024-02-20
$299.44M
10-K · filed 2024-02-20
2021-09-30$121.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08
$158.63M
derived: sum of 2 quarters · filed 2022-11-08
$216.92M
10-Q · filed 2022-11-08
$267.84M
derived: sum of 4 quarters · filed 2023-02-21
2021-06-30$36.89M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
$95.19M
10-Q · filed 2022-08-09
$146.10M
derived: sum of 3 quarters · filed 2023-02-21
$152.19M
derived: sum of 4 quarters · filed 2023-02-21
2021-03-31$58.30M
10-Q · filed 2022-05-10
$109.22M
derived: sum of 2 quarters · filed 2023-02-21
$115.30M
derived: sum of 3 quarters · filed 2023-02-21
$118.59M
derived: sum of 4 quarters · filed 2023-02-21
2020-12-31$50.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21
$57.00M
derived: sum of 2 quarters · filed 2023-02-21
$60.30M
derived: sum of 3 quarters · filed 2023-02-21
$55.45M
10-K · filed 2023-02-21
2020-09-30$6.08M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02
$9.38M
derived: sum of 2 quarters · filed 2021-11-02
$4.53M
10-Q · filed 2021-11-02
-$22.09M
derived: sum of 4 quarters · filed 2022-02-22
2020-06-30$3.29M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09
-$1.55M
10-Q · filed 2021-08-09
-$28.18M
derived: sum of 3 quarters · filed 2022-02-22
-$57.76M
derived: sum of 4 quarters · filed 2022-02-22
2020-03-31-$4.84M
10-Q · filed 2021-05-10
-$31.47M
derived: sum of 2 quarters · filed 2022-02-22
-$61.06M
derived: sum of 3 quarters · filed 2022-02-22
-$85.84M
derived: sum of 4 quarters · filed 2022-02-22
2019-12-31-$26.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-22
-$56.21M
derived: sum of 2 quarters · filed 2022-02-22
-$81.00M
derived: sum of 3 quarters · filed 2022-02-22
-$85.42M
10-K · filed 2022-02-22
2019-09-30-$29.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02
-$54.37M
derived: sum of 2 quarters · filed 2020-11-02
-$58.80M
10-Q · filed 2020-11-02
-$48.34M
derived: sum of 4 quarters · filed 2021-02-23
2019-06-30-$24.79M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
-$29.21M
10-Q · filed 2020-08-10
-$18.75M
derived: sum of 3 quarters · filed 2021-02-23
-$37.67M
derived: sum of 4 quarters · filed 2021-02-23
2019-03-31-$4.42M
10-Q · filed 2020-05-11
$6.04M
derived: sum of 2 quarters · filed 2021-02-23
-$12.89M
derived: sum of 3 quarters · filed 2021-02-23
-$31.75M
derived: sum of 4 quarters · filed 2021-02-23
2018-12-31$10.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23
-$8.46M
derived: sum of 2 quarters · filed 2021-02-23
-$27.32M
derived: sum of 3 quarters · filed 2021-02-23
-$49.50M
10-K · filed 2021-02-23
2018-09-30-$18.93M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$37.78M
derived: sum of 2 quarters · filed 2019-11-12
-$59.96M
10-Q · filed 2019-11-12
2018-06-30-$18.86M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06
-$41.03M
10-Q · filed 2019-08-06
2018-03-31-$22.18M
10-Q · filed 2019-05-07
2017-12-31$134.05M
10-K · filed 2020-02-24
2016-12-31-$50.38M
10-K · filed 2017-02-28
2015-12-31-$37.08M
10-K · filed 2017-02-28
2015-06-30$8.94M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10
-$4.90M
10-Q · filed 2015-08-10
-$5.84M
derived: sum of 3 quarters · filed 2017-02-28
-$19.02M
derived: sum of 4 quarters · filed 2017-02-28
2015-03-31-$13.84M
10-Q · filed 2015-05-11
-$14.78M
derived: sum of 2 quarters · filed 2017-02-28
-$27.96M
derived: sum of 3 quarters · filed 2017-02-28
-$43.73M
derived: sum of 4 quarters · filed 2017-02-28
2014-12-31-$939.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28
-$14.12M
derived: sum of 2 quarters · filed 2017-02-28
-$29.89M
derived: sum of 3 quarters · filed 2017-02-28
-$47.52M
10-K · filed 2017-02-28
2014-09-30-$13.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
-$28.95M
derived: sum of 2 quarters · filed 2015-08-10
-$46.58M
10-Q · filed 2014-11-10
-$61.80M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30-$15.77M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10
-$33.40M
10-Q · filed 2015-08-10
-$48.62M
derived: sum of 3 quarters · filed 2016-02-29
-$61.03M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31-$17.63M
10-Q · filed 2015-05-11
-$32.85M
derived: sum of 2 quarters · filed 2016-02-29
-$45.26M
derived: sum of 3 quarters · filed 2016-02-29
-$56.22M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31-$15.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
-$27.63M
derived: sum of 2 quarters · filed 2016-02-29
-$38.59M
derived: sum of 3 quarters · filed 2016-02-29
-$49.34M
10-K · filed 2016-02-29
-$49.34M
10-K · filed 2014-02-28
2013-09-30-$12.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
-$23.37M
derived: sum of 2 quarters · filed 2014-11-10
-$34.12M
10-Q · filed 2014-11-10
-$34.12M
10-Q · filed 2013-11-08
-$50.99M
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30-$10.96M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11
-$21.70M
10-Q · filed 2014-08-11
-$21.71M
10-Q · filed 2013-08-07
-$38.57M
derived: sum of 3 quarters · filed 2015-03-02
-$52.87M
derived: sum of 4 quarters · filed 2015-03-02
2013-03-31-$10.75M
10-Q · filed 2014-05-12
-$10.75M
10-Q · filed 2013-05-08
-$27.62M
derived: sum of 2 quarters · filed 2015-03-02
-$41.92M
derived: sum of 3 quarters · filed 2015-03-02
-$55.67M
derived: sum of 4 quarters · filed 2015-03-02
2012-12-31-$16.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
-$31.17M
derived: sum of 2 quarters · filed 2015-03-02
-$44.92M
derived: sum of 3 quarters · filed 2015-03-02
-$64.28M
10-K · filed 2015-03-02
-$64.33M
10-K · filed 2013-03-01
2012-09-30-$14.30M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
-$28.05M
derived: sum of 2 quarters · filed 2013-11-08
-$47.41M
10-Q · filed 2013-11-08
-$60.91M
derived: sum of 4 quarters · filed 2014-02-28
2012-06-30-$13.76M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-07
-$33.11M
10-Q · filed 2013-08-07
-$46.62M
derived: sum of 3 quarters · filed 2014-02-28
-$60.06M
derived: sum of 4 quarters · filed 2014-02-28
2012-03-31-$19.36M
10-Q · filed 2013-05-08
-$32.86M
derived: sum of 2 quarters · filed 2014-02-28
-$46.30M
derived: sum of 3 quarters · filed 2014-02-28
-$42.57M
derived: sum of 4 quarters · filed 2014-02-28
2011-12-31-$13.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28
-$26.95M
derived: sum of 2 quarters · filed 2014-02-28
-$23.21M
derived: sum of 3 quarters · filed 2014-02-28
-$34.30M
10-K · filed 2014-02-28
-$34.35M
10-K · filed 2012-03-12
2011-09-30-$13.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08
-$9.70M
derived: sum of 2 quarters · filed 2012-11-08
-$20.80M
10-Q · filed 2012-11-08
-$28.17M
derived: sum of 4 quarters · filed 2013-03-01
2011-06-30$3.74M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
-$7.35M
10-Q · filed 2012-08-09
-$14.73M
derived: sum of 3 quarters · filed 2013-03-01
-$26.34M
derived: sum of 4 quarters · filed 2013-03-01
2011-03-31-$11.09M
10-Q · filed 2012-05-07
-$18.47M
derived: sum of 2 quarters · filed 2013-03-01
-$30.08M
derived: sum of 3 quarters · filed 2013-03-01
2010-12-31-$7.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-01
-$18.99M
derived: sum of 2 quarters · filed 2013-03-01
-$45.39M
10-K · filed 2013-03-01
2010-09-30-$11.62M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08
-$38.01M
10-Q · filed 2011-11-08
2010-06-30-$26.39M
10-Q · filed 2011-08-05
2009-12-31-$40.15M
10-K · filed 2012-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
Immunovant, Inc. (IMVT)United States$7.028B-14.78